%	O
%	O
TITLE	O

Characterization	O
of	O
key	O
transcription	O
factors	O
as	O
molecular	O
signatures	O
of	O
HPV	O
-	O
positive	O
and	O
HPV	O
-	O
negative	O
oral	O
cancers	O
.	O

%	O
%	O
ABSTRACT	O

Prior	O
studies	O
established	O
constitutively	O
active	O
AP	O
-	O
1	O
,	O
NF	O
-	O
ÎºB	O
,	O
and	O
STAT3	O
signaling	O
in	O
oral	O
cancer	O
.	O

Differential	O
expression	O
/	O
activation	O
of	O
specific	O
members	O
of	O
these	O
transcription	O
factors	O
has	O
been	O
documented	O
in	O
HPV	O
-	O
positive	O
oral	O
lesions	O
that	O
respond	O
better	O
to	O
therapy	O
.	O

We	O
performed	O
a	O
comprehensive	B-Study_Type
analysis	I-Study_Type
of	O
differentially	O
expressed	O
,	O
transcriptionally	O
active	O
members	O
of	O
these	O
pivotal	O
signaling	O
mediators	O
to	O
develop	O
specific	O
signatures	O
of	O
HPV	O
-	O
positive	O
and	O
HPV	O
-	O
negative	O
oral	O
lesions	O
by	O
immunohistochemical	O
method	O
that	O
is	O
applicable	O
in	O
low	O
-	O
resource	O
settings	O
.	O

We	O
examined	O
a	O
total	O
of	O
31	O
prospective	O
and	O
30	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
treatment	O
-	O
naÃ¯ve	O
,	O
histopathologically	O
and	O
clinically	O
confirmed	O
cases	O
diagnosed	O
as	O
oral	O
or	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
/	O
OPSCC	O
)	O
.	O

Following	O
determination	O
of	O
their	O
HPV	O
status	O
by	O
GP5Â	O
+	O
Â	O
/	O
GP6Â	O
+	O
Â	O
PCR	B-HPV_Lab_Technique
,	I-HPV_Lab_Technique
the	O
sequential	O
sections	O
of	O
the	O
tissues	B-HPV_Sample_Type
were	O
evaluated	O
for	O
expression	O
of	O
JunB	O
,	O
JunD	O
,	O
c	O
-	O
Fos	O
,	O
p50	O
,	O
p65	O
,	O
STAT3	O
,	O
and	O
pSTAT3	O
(	O
Y705	O
)	O
,	O
along	O
with	O
two	O
key	O
regulatory	O
proteins	O
pEGFR	O
and	O
p16	B-HPV_Lab_Technique
by	I-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
.	O

Independent	O
analysis	O
of	O
JunB	O
and	O
p65	O
showed	O
direct	O
correlation	O
with	O
HPV	O
positivity	O
,	O
whereas	O
STAT3	O
and	O
pSTAT3	O
were	O
inversely	O
correlated	O
.	O

A	O
combined	O
analysis	O
of	O
transcription	O
factors	O
revealed	O
a	O
more	O
restrictive	O
combination	O
,	O
characterized	O
by	O
the	O
presence	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
ÎºB	O
lacking	O
involvement	O
of	O
STAT3	O
that	O
strongly	O
correlated	O
with	O
HPV	O
-	O
positive	O
tumors	O
.	O

Presence	O
of	O
STAT3	O
/	O
pSTAT3	O
with	O
NF	O
-	O
ÎºB	O
irrespective	O
of	O
the	O
presence	O
or	O
absence	O
of	O
AP	O
-	O
1	O
members	O
was	O
present	O
in	O
HPV	O
-	O
negative	O
lesions	O
.	O

Expression	O
of	O
pSTAT3	O
strongly	O
correlated	O
with	O
all	O
the	O
AP	O
-	O
1	O
/	O
NF	O
-	O
ÎºB	O
members	O
(	O
except	O
JunD	O
)	O
,	O
its	O
upstream	O
activator	O
pEGFR	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Clinical	O
specimens	B-HPV_Sample_Type
and	O
study	O
design	O

A	B-Study_Cohort
total	I-Study_Cohort
of	I-Study_Cohort
116	I-Study_Cohort
prospectively	I-Study_Cohort
collected	I-Study_Cohort
fresh	I-Study_Cohort
biopsies	I-Study_Cohort
and	I-Study_Cohort

30	I-Study_Cohort
formalin	I-Study_Cohort
-	I-Study_Cohort
fixed	I-Study_Cohort
paraffin	I-Study_Cohort
-	I-Study_Cohort
embedded	I-Study_Cohort
preserved	I-Study_Cohort
tissues	I-Study_Cohort
(	I-Study_Cohort
retrospective	I-Study_Cohort
)	I-Study_Cohort
from	I-Study_Cohort
treatment	I-Study_Cohort
-	I-Study_Cohort
naïve	I-Study_Cohort
,	I-Study_Cohort
histopathologically	I-Study_Cohort
and	I-Study_Cohort
clinically	I-Study_Cohort
confirmed	I-Study_Cohort
cases	I-Study_Cohort
diagnosed	I-Study_Cohort
as	I-Study_Cohort
oral	I-Study_Cohort
or	I-Study_Cohort
oro	I-Study_Cohort
-	I-Study_Cohort
pharyngeal	I-Study_Cohort
squamous	I-Study_Cohort
cell	I-Study_Cohort
carcinoma	I-Study_Cohort
(	I-Study_Cohort
OSCC	I-Study_Cohort
/	I-Study_Cohort
OPSCC	I-Study_Cohort
)	I-Study_Cohort
were	O
obtained	O
from	O
three	O
tertiary	O
cancer	O
care	O
hospitals	O
[	O
Department	O
of	O
Medical	O
Oncology	O
,	O
Rajiv	O
Gandhi	O
Cancer	O

Institute	O
&	O
Research	O
Centre	O
(	O
RGCI	O
)	O
,	O
New	O
Delhi	O
;	O
Department	O
of	O
Surgical	O
Oncology	O
,	O
All	O
India	B-Study_Location
Institute	O
of	O
Medical	O
Sciences	O
(	O
AIIMS	O
)	O
,	O
New	O
Delhi	O
;	O
Department	O
of	O
Medicine	O
,	O
Lady	O
Harding	O
Medical	O
College	O
(	O
LHMC	O
)	O
,	O
New	O
Delhi	O
]	O
and	O
a	O
dental	O
hospital	O
[	O
Subharti	O
Dental	O
College	O
and	O
Hospital	O
(	O
SDCH	O
)	O
,	O
Meerut	O
]	O
.	O

In	O
addition	O
,	O
paraffin	O
-	O
embedded	O
tissue	B-HPV_Sample_Type
sections	O
were	O
also	O
available	O
for	O
36	O
oral	O
cancer	O
cases	O
Figure	O
1	O
.	O

Four	O
fresh	O
tissues	B-HPV_Sample_Type
and	O
10	O
paraffin	O
blocks	O
were	O
obtained	O
either	O
from	O
normal	O
individuals	O
or	O
from	O
suspected	O
cases	O
but	O
with	O
normal	O
histology	O
or	O
who	O
attended	O
dental	O
clinics	O
for	O
unrelated	O
problems	O
or	O
had	O
undergone	O
tooth	O
extraction	O
.	O

These	O
tissues	B-HPV_Sample_Type
were	O
used	O
as	O
controls	O
for	O
the	O
study	O
.	O

Prior	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
the	O
patients	O
and	O
control	O
subjects	O
included	O
in	O
the	O
study	O
according	O
to	O
the	O
principle	O
laid	O
down	O
by	O
the	O
declaration	O
of	O
Helsinki	O
,	O
and	O
the	O
epidemiological	O
details	O
were	O
taken	O
from	O
their	O
clinical	O
records	O
.	O

The	O
clinical	O
characteristics	O
of	O
these	O
patients	O
are	O
presented	O
in	O
Table	O
S1	O
.	O

DNA	O
was	O
isolated	O
from	O
fresh	O
and	O
paraffin	O
sections	O
for	O
all	O
the	O
available	O
tis	B-HPV_Sample_Type
-	I-HPV_Sample_Type
sues	I-HPV_Sample_Type
,	I-HPV_Sample_Type
wherein	O
135	O
cases	O
qualified	O
for	O
HPV	O
analysis	O
.	O

Out	O
of	O
66	O
FFPE	O
tissues	B-HPV_Sample_Type
,	I-HPV_Sample_Type
61	O
were	O
analyzable	O
for	O
HPV	O
positivity	O
and	O
marker	O
expression	O
by	O
IHC	B-HPV_Lab_Technique
analysis	O
.	O

Fourteen	O
fresh	O
biopsies	B-HPV_Sample_Type
and	O
four	O
normal	O
control	O
tissues	B-HPV_Sample_Type
were	O
available	O
for	O
evaluation	O
of	O
protein	O
markers	O
and	O
other	O
molecular	O
investigations	O
.	O

All	O
the	O
patients	O
were	O
chosen	O
prior	O
to	O
any	O
chemotherapy	O
or	O
radiotherapy	O
treatment	O
.	O

While	O
the	O
biopsy	B-HPV_Sample_Type
was	O
sent	O
for	O
histopathological	O
diagnosis	O
in	O
formalin	O
solu	O
-	O
tion	O
as	O
routine	O
strategy	O
,	O
wherever	O
possible	O
,	O
a	O
portion	O
of	O
fresh	O
biopsy	B-HPV_Sample_Type
collected	O
in	O
sterile	O
cold	O
1×	O
phosphate	O
buffer	O
saline	O
(	O
PBS	O
)	O
was	O
immediately	O
processed	O
for	O
molecular	O

analysis	O
or	O
stored	O
at	O
−80°C	O
until	O
further	O
used	O
.	O

The	O
Institutional	O
Ethics	O
Committee	O
of	O
collaborating	O
hospitals	O
and	O
Institute	O
of	O
Cytology	O
&	O
Preventive	O
Oncology	O
(	O
ICPO	O
)	O
,	O
Noida	O
,	O
India	B-Study_Location
,	I-Study_Location
where	O
the	O
laboratory	O
work	O
was	O
carried	O
out	O
,	O
approved	O
the	O
study	O
protocol	O
.	O

Materials	O

All	O
antibodies	O
(	O
except	O
	O
-	O
actin	O
)	O
and	O
ABC	O
staining	O
kits	O
were	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Antibodies	O
and	O
their	O
clonal	O
description	O
are	O
listed	O
in	O
Table	O
S2	O
.	O

Primers	O
/	O
oligonucleotides	O
were	O
custom	O
-	O
synthesized	O
from	O
Microsynth	O
(	O
Lindau	O
,	O
Germany	O
)	O
or	O
Eurogentec	O
(	O
Seraing	O
,	O
Belgium	O
)	O
listed	O
in	O
Table	O
S3	O
.	O

Immobilon	O
-	O
P	O
PVDF	O
mem	O
-	O
branes	O
was	O
from	O
Millipore	O
Corporation	O
(	O
MA	O
,	O
USA	O
)	O
,	O
xylene	O
from	O
Fisher	O
Scientific	O
(	O
PA	O
,	O
USA	O
)	O
,	O
absolute	O
ethanol	O
and	O
H2O2	O
were	O
procured	O
from	O
Merck	O
(	O
CA	O
,	O
USA	O
)	O
.	O

Tween	O
-	O
20	O
,	O
3	O
,	O
30	O
-	O
Diaminobenzidine	O
(	O
DAB	O
)	O
,	O
Meyer’s	O
hematoxylin	O
and	O
all	O
other	O
reagents	O
used	O
in	O
the	O
study	O
were	O
of	O
analytical	O
and	O
molecular	O
biology	O
grade	O
and	O
were	O
procured	O
from	O
Sigma	O
Aldrich	O
(	O
MO	O
,	O
USA	O
)	O
unless	O
specified	O
otherwise	O
.	O

Genomic	O
DNA	O
Isolation	O
and	O
HPV	O
detection	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
freshly	O
collected	O
OSCC	O
biopsies	O
by	O
the	O
standard	O
proteinase	O
K	O
digestion	O
followed	O
by	O
phenol	O
-	O
chloroform	O
extraction	O
and	O
PCR	B-HPV_Lab_Technique
amplification	O
performed	O
following	O
the	O
procedure	O
described	O
earlier	O
[	O
19	O
]	O
.	O

Genomic	O
DNA	O
extraction	O
from	O
FFPE	O
scrape	O
specimens	B-HPV_Sample_Type
(	O
5	O
sections	O
of	O
5	O
μm	O
thickness	O
)	O
was	O
performed	O
according	O

Figure	O
1	O
.	O

Work	O
flow	O
of	O
sample	B-HPV_Sample_Type
collection	O
and	O
processing	O
for	O
HPV	O
analysis	O
and	O
expression	O
analysis	O
for	O
transcription	O
factors	O
.	O

Prospectively	O
collected	O
,	O
paired	O
fresh	O
and	O
formalin	O
-	O
fixed	O
tissues	B-HPV_Sample_Type
,	O
and	O
retrospective	O
tissue	B-HPV_Sample_Type
sections	O
were	O
evaluated	O
for	O
optimization	O
of	O
protocol	O
for	O
detection	O
of	O
HPV	O
infection	O
and	O
expression	O
of	O
transcription	O
factors	O
in	O
oral	O
cancer	O
cases	O
by	O
molecular	O
methods	O
and	O
IHC	B-HPV_Lab_Technique
.	O
*	O
Four	O
fresh	O
tissues	B-HPV_Sample_Type
and	O
10	O
paraffin	O
blocks	O
of	O
noncancerous	O
patients	O
were	O
also	O
collected	O
as	O
controls	O
with	O
prior	O
consent	O
from	O
dental	O
clinic	O
and	O
processed	O
similarly	O
for	O
HPV	O
detection	O
and	O
IHC	B-HPV_Lab_Technique
not	O
depicted	O
in	O
the	O
diagram	O
.	O

to	O
xylene	O
-	O
free	O
method	O
with	O
slight	O
modification	O
[	O
27	O
]	O
.	O

Prior	O
to	O
detection	O
of	O
HPV	O
infection	O
,	O
the	O
adequacy	O
of	O
DNA	O
was	O
assessed	O
by	O
subjecting	O
the	O
genomic	O
DNA	O
(	O
100	O
ng	O
/	O
reaction	O
)	O
for	O
p53	O
Exon	O
5	O
PCR	B-HPV_Lab_Technique
,	I-HPV_Lab_Technique
which	O
was	O
used	O
as	O
internal	O
control	O
.	O

HPV	O
infection	O
was	O
detected	O
by	O
a	O
PCR	B-HPV_Lab_Technique
-	O
based	O
method	O
using	O
consensus	O
sequence	O
-	O
specific	O
primers	O
GP5	O
+	O
/	O
GP6	O
+	O
or	O
type	O
-	O
specific	O
primers	O
for	O
HPV16	O
and	O
HPV18	O
.	O

PCR	B-HPV_Lab_Technique
was	O
performed	O
in	O
a	O
25	O
μL	O
reaction	O
mixture	O
containing	O
100	O
ng	O
DNA	O
,	O
10	O
mmol	O
/	O
L	O
Tris	O
-	O
HCl	O
(	O
pH	O
8	O
.	O
4	O
)	O
,	O
50	O
mmol	O
/	O
L	O
KCl	O
,	O

1	O
.	O
5	O
mmol	O
/	O
L	O
MgCl2	O
,	O
125	O
mmol	O
/	O
L	O
of	O
each	O
dNTPs	O
(	O
MBI	O
fermentas	O
,	O
Ontario	O
,	O
Canada	O
)	O
,	O
5pmol	O
of	O
oligonucleotide	O
primers	O
,	O
and	O
0	O
.	O
5U	O
Taq	O
DNA	O
polymerase	O
(	O
B	O
.	O

Genei	O
(	O
Merck	O
)	O
,	O
Indi	O
)	O
in	O
ABI2720	O
Thermalcycler	O
[	O
Applied	O
Biosystems	O
Inc	O
.	O

(	O
Thermo	O
Fisher	O
)	O
]	O
.	O

The	O
temperature	O
profile	O
used	O
for	O
ampli	O
-	O
fication	O
constituted	O
an	O
initial	O
denaturation	O
at	O
95°C	O
for	O
4	O
min	O
followed	O
by	O
30	O
cycles	O
of	O
denaturation	O
at	O
95°C	O
for	O

30	O
sec	O
,	O
annealing	O
at	O
55°C	O
for	O
30	O
sec	O
,	O
and	O
extension	O
at	O
72°C	O
for	O
1	O
min	O
,	O
which	O
was	O
extended	O
for	O
5	O
min	O
at	O
the	O
final	O
cycle	O
.	O

Details	O
of	O
primers	O
used	O
for	O
HPV	O
detection	O
and	O
genotyping	O
for	O
HPV16	O
and	O
HPV18	O
are	O
presented	O
in	O
Table	O
S3	O
.	O

Isolation	O
of	O
total	O
protein	O
from	O
oral	O
cancer	O
tissues	B-HPV_Sample_Type

Total	O
proteins	O
from	O
biopsies	B-HPV_Sample_Type
were	O
prepared	O
by	O
the	O
method	O
described	O
previously	O
[	O
19	O
]	O
.	O

Briefly	O
,	O
the	O
method	O
involved	O
a	O
fine	O
mincing	O
of	O
either	O
fresh	O
or	O
frozen	O
biopsies	B-HPV_Sample_Type
stored	O
at	O

−80°C	O
,	O
in	O
chilled	O
PBS	O
with	O
the	O
help	O
of	O
surgical	O
blades	O
in	O
a	O
petridish	O
kept	O
on	O
ice	O
.	O

The	O
minced	O
tissue	B-HPV_Sample_Type
material	O
was	O
centrifuged	O
at	O
1469g	O
at	O
4°C	O
to	O
wash	O
off	O
1×	O
PBS	O
solution	O
.	O

Pellet	O
was	O
resuspended	O
in	O
lysis	O
buffer	O
(	O
20	O
mmol	O
/	O
L	O
Tris	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
250	O
mmol	O
/	O
L	O
NaCl	O
,	O
2	O
mmol	O
/	O
L	O
EDTA	O
(	O
pH	O
8	O
.	O
0	O
)	O
,	O

0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
0	O
.	O
01	O
mg	O
/	O
mL	O
aprotinin	O
,	O
0	O
.	O
005	O
mg	O
/	O
mL	O
leupeptin	O
,	O
0	O
.	O
4	O
mmol	O
/	O
L	O
PMSF	O
,	O
and	O
4	O
mmol	O
/	O
L	O
Na3VO4	O
)	O
.	O

Lysates	O
were	O
spun	O
at	O
18001g	O
for	O
10	O
min	O
to	O
remove	O
par	O
-	O
ticulate	O
components	O
.	O

The	O
concentration	O
of	O
proteins	O
was	O
then	O
determined	O
in	O
the	O
supernatant	O
by	O
standard	O
Bradford	O
assay	O
.	O

Protein	O
samples	B-HPV_Sample_Type
were	O
stored	O
in	O
small	O
aliquots	O
at	O

−80°C	O
till	O
further	O
use	O
.	O

Immunoblotting	O

Immunoblotting	O
was	O
performed	O
as	O
per	O
routine	O
laboratory	O
method	O
described	O
earlier	O
[	O
19	O
]	O
.	O

List	O
of	O
specific	O
antibodies	O
against	O
c	O
-	O
Fos	O
,	O
JunB	O
,	O
JunD	O
,	O
c	O
-	O
Jun	O
,	O
p50	O
,	O
p65	O
,	O
p16	O
,	O
STAT3	O
,	O
pSTAT3	O
,	O
and	O
EGFR	O
and	O
dilutions	O
are	O
mentioned	O
in	O
Table	O
S2	O
.	O

Detailed	O
methodology	O
is	O
included	O
as	O
Data	O
S3	O
.	O

Immunohistochemistry	B-HPV_Lab_Technique

Immunohistochemistry	B-HPV_Lab_Technique
was	O
performed	O
as	O
per	O
routine	O
laboratory	O
method	O
described	O
earlier	O
[	O
19	O
]	O
.	O

List	O
of	O
specific	O

antibodies	O
and	O
dilutions	O
are	O
mentioned	O
in	O
Table	O
S2	O
.	O

Detailed	O
methodology	O
is	O
included	O
as	O
Data	O
S3	O
.	O

Histopathological	O
and	O
IHC	B-HPV_Lab_Technique
evaluation	O

Two	O
independent	O
pathologists	O
performed	O
the	O
histopatho	O
-	O
logical	O
evaluation	O
of	O
hematoxylin	O
and	O
eosin	O
-	O
stained	O
tissue	B-HPV_Sample_Type
sections	O
as	O
per	O
routine	O
procedure	O
.	O

Scoring	O
of	O
IHC	B-HPV_Lab_Technique
staining	O
was	O
performed	O
by	O
two	O
independent	O
investigators	O
(	O
GV	O
and	O
AT	O
)	O
.	O

In	O
cancer	O
cases	O
,	O
all	O
the	O
cells	O
were	O
analyzed	O
for	O
c	O
-	O
Fos	O
,	O
JunB	O
,	O
JunD	O
,	O
c	O
-	O
Jun	O
,	O
p50	O
,	O
p65	O
,	O
p16	O
,	O
STAT3	O
,	O
pSTAT3	O
,	O
and	O
EGFR	O
immunostaining	O
.	O

Overall	O
inter	O
-	O
observer	O
difference	O
varied	O
between	O
5–10	O
%	O
.	O

Discrepant	O
scores	O
were	O
resolved	O
by	O
third	O
evaluation	O
(	O
ACB	O
)	O
.	O

Every	O
IHC	B-HPV_Lab_Technique
-	O
stained	O
tissue	B-HPV_Sample_Type
was	O
scored	O
as	O
reported	O
earlier	O
[	O
20	O
]	O
on	O
an	O
arbitrary	O
scale	O
accord	O
-	O
ing	O
to	O
the	O
number	O
of	O
positively	O
stained	O
cells	O
and	O
overall	O
staining	O
intensity	O
of	O
the	O
section	O
and	O
assigned	O
a	O
value	O
ranging	O
from	O
Nil	O
(	O
-	O
)	O
:	O
no	O
staining	O
;	O
Weak	O
(	O
+	O
)	O
:	O
1–10	O
%	O
cells	O
showing	O
focal	O
positivity	O
;	O
Moderate	O
(	O
+	O
+	O
)	O
:	O
11–50	O
%	O
cells	O
showing	O
focal	O
or	O
diffused	O
positivity	O
;	O
and	O
Strong	O
(	O
+	O
+	O
+	O
)	O
:	O
more	O
than	O
50	O
%	O
cells	O
showing	O
diffused	O
positivity	O
.	O

Statistical	O
analysis	O

To	O
determine	O
association	O
between	O
the	O
epidemiological	O
and	O
clinicopathological	O
characteristics	O
,	O
Mann–Whitney	O
test	O
and	O
Chi	O
-	O
square	O
test	O
were	O
employed	O
,	O
using	O
SPSS	O
Statistics	O
Software	O
version	O
2015	O
(	O
IBM	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Chi	O
-	O
square	O
test	O
and	O
Fisher’s	O
exact	O
test	O
(	O
for	O
smaller	O
numbers	O
on	O
sub	O
-	O
group	O
analysis	O
)	O
were	O
employed	O
to	O
analyze	O
association	O
between	O
the	O
expression	O
of	O
proteins	O
among	O
different	O
his	O
-	O
topathological	O
grades	O
of	O
tissue	B-HPV_Sample_Type
biopsies	I-HPV_Sample_Type
using	O
SPSS	O
Statistics	O
Software	O
version	O
2015	O
(	O
IBM	O
Chicago	O
)	O
.	O

For	O
all	O
analyses	O
,	O
P	O
	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

